ClinicaliQ Trial Snapshot
- A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer — Active Not Recruiting • Phase I / Phase II • Oncology • NCT03742102.
- Trial testing durvalumab combinations versus standard chemotherapy in patients with advanced triple negative breast cancer.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer Conditions: Triple Negative Breast Neoplasms Interventions: Durvalumab, Capivasertib, Oleclumab, Paclitaxel, Trastuzumab deruxtecan, Datopotamab deruxtecan Lead Sponsor: AstraZeneca Planned Enrollment: 243 participants